FUCHS-PETROLUB-SE
The FUCHS Group, which operates globally in the lubricants industry, brings new small packs for the automotive sector onto the market, maximizing customer benefits: new labels for better orientation, ergonomic design for better handling, and gentle on resources thanks to the use of recycled material. The new small packs will be implemented gradually in the FUCHS companies from November 15, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005059/en/
The range of lubricant products in the automotive sector is enormous – and for customers it's getting harder and harder to find what they need. The new small packs for all automotive FUCHS product brands – TITAN, AGRIFARM, MAINTAIN, PLANTO, and SILKOLENE – rise to this challenge: The Group has optimized its small packs globally for the quantities 1, 4, and 5 liters, not just visually but also in terms of handling and environmental friendliness. "The unique new design makes it easier for our customers to choose the right product, improves user-friendliness, and saves on resources," sums up Krisztián Rada, Head of Automotive Aftermarket Division.
Easy to choose
The new clearly structured design of the labels enables customers to identify all the relevant information at a glance. Colors, images, and pictograms help with orientation. For instance, the quality levels of the products are clearly indicated by the color codes gold, silver, and bronze. The most important information the customer needs to know about the lubricant is given in concise and comprehensible way, such as the viscosity of the product and area of application – for cars, trucks, or tractors.
Easy to use
The new ergonomically shaped bottles are easy to open without tools, fit better in the hand, and are easier for the user to handle. For example, the enlarged opening of the bottle and an optimized neck design allow accurate filling with no drops. Two handles make the 4 and 5-liter bottles more comfortable to carry and facilitate filling. What's more, the new tamper-resistant cap ensures that the bottle has not been opened before and that if FUCHS is written on it, there is FUCHS inside it.
Easy on the environment :
FUCHS has been pursuing its sustainability strategy for almost ten years now, with the objective of carbon neutrality according to the "avoid – reduce – compensate" principle. As such, all FUCHS lubricants in the Group's plants are produced carbon-neutrally. The bottle material of the new small packs consists of up to 30 percent recycled material (PCR) and is 100-percent recyclable. The improved bottle shape of the bottle also makes it possible to pour out even the smallest remaining volume of fluid, allowing complete emptying of the bottles. "Our new small packs are not just intended to be more user-friendly but also contribute to avoiding waste, enable materials to be recycled, and help to reduce carbon footprints. FUCHS will continue to work toward making our packaging continuously more sustainable in the future, too," says Markus Garb, Vice President Sustainability, stating a further objective of the innovation.
The following information material is available online:
About FUCHS
FUCHS develops, produces and markets high-grade lubricants and related specialties for virtually all industries and areas of application. The company, which was founded in Mannheim in 1931, employs around 6,000 people worldwide at 58 operating companies. FUCHS is the world's largest independent lubricant manufacturer. The most important markets in terms of sales revenue are Western Europe, Asia and North America.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005059/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
